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Abstract Oxysterols are oxidized derivatives of
cholesterol that play regulatory roles in lipid
biosynthesis and homeostasis. How oxysterol
signaling coordinates different lipid classes such as
sterols and triglycerides remains incompletely un-
derstood. Here, we show that 4β-hydroxycholesterol
(HC) (4β-HC), a liver and serum abundant oxysterol
of poorly defined functions, is a potent and selective
inducer of the master lipogenic transcription factor,
SREBP1c, but not the related steroidogenic tran-
scription factor SREBP2. By correlating tracing of
lipid synthesis with lipogenic gene expression
profiling, we found that 4β-HC acts as a putative
agonist for the liver X receptor (LXR), a sterol sensor
and transcriptional regulator previously linked to
SREBP1c activation. Unique among the oxysterol ag-
onists of the LXR, 4β-HC induced expression of the
lipogenic program downstream of SREBP1c and trig-
gered de novo lipogenesis both in primary hepato-
cytes and in the mouse liver. In addition, 4β-HC acted
in parallel to insulin-PI3K–dependent signaling to
stimulate triglyceride synthesis and lipid-droplet
accumulation. Thus, 4β-HC is an endogenous
regulator of de novo lipogenesis through the LXR-
SREBP1c axis.
Supplementary key words oxysterol • SREBP1c • liver-X-
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All cells must achieve and maintain a balanced
composition of their internal membranes to grow,
proliferate, or adapt to sudden changes in external
conditions and nutrient availability (1). Dedicated
biosynthetic pathways mediate the synthesis of fatty
acids, sterols, phospholipids, and sphingolipids, but how
these pathways communicate with each other to coor-
dinate their respective activities and respond to
changing metabolic needs is poorly understood (2, 3).
The liver X receptor (LXR) α and β are transcription
factors belonging to the nuclear receptor superfamily
that play key roles in maintaining lipid homeostasis in
multiple cells and organs (4–7). The LXRα and LXRβ
dimerize with the retinoid X receptor (RXR) and acti-
vate target genes that mediate cholesterol efflux from
cells, including ABC-family transporters, as well as
genes that mediate conversion of cholesterol into bile
acids in the liver to facilitate cholesterol elimination
from the body, such as cytochrome p450 7a-hydroxy-
lase (8–10). Accordingly, mice lacking the LXRα exhibit
impaired bile acid metabolism and defective choles-
terol elimination (9), along with enhanced inflamma-
tion and formation of atherosclerotic plaques (11).
Conversely, synthetic LXRα agonists have shown
promise in reducing atherosclerosis and preventing
cardiovascular disease in animal models (12–14).
Another key mediator of lipid homeostasis is the
helix-loop-helix-leucine zipper transcription factor,
SREBP1c. SREBP1c is a master regulator of biosynthesis
of fatty acids and triglycerides [collectively referred to
as de novo lipogenesis (DNL)] that is subject to tight
transcriptional and posttranslational regulation. Along
with its paralogue, the master steroidogenic transcrip-
tion factor SREBP2, SREBP1c resides at the endo-
plasmic reticulum (ER) membrane, to which it is
anchored via a single transmembrane helix. When
cholesterol concentration in the ER membrane is low,
SREBP1c and SREBP2 are transported to the Golgi
apparatus via interaction with SREBP cleavage-
activating protein, a cholesterol-sensing chaperone
that favors their loading into COPII vesicles. At the
Golgi membrane, resident proteases cleave the DNA-
binding portion of SREBP1c and SREBP2 from the
transmembrane portion, enabling their translocation to
the nucleus and activation of downstream programs for
DNL and de novo steroidogenesis, respectively.*For correspondence: Roberto Zoncu, rzoncu@berkeley.edu.
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In addition to their homeostatic regulation by
cholesterol levels, the SREBPs lie downstream of
metabolic hormone signaling. For example, in the liver,
both the expression and proteolytic activation of
SREBP1c are stimulated by the insulin-
phosphatidylinositol 3-kinase (PI3K)-mechanistic
Target of Rapamycin (mTOR) pathway, as part of a
mechanism that converts excess of glucose into lipids,
which are required for energy storage (15–17). However,
the range of regulatory inputs to SREBP1c and their
respective interplay remain to be fully elucidated.
The LXRα and LXRβ were shown to directly bind to
the promoter of the SREBP1c gene and trigger activa-
tion of its downstream lipogenic genes (6). Accordingly,
synthetic LXR ligands strongly promote DNL and
increased plasma triglyceride levels (13, 18, 19),
providing evidence for cross-talk between LXR- and
SREBP1c-dependent programs.
Although the physiological significance of LXR-
dependent regulation of DNL through SREBP1c re-
mains unclear, this cross-talk has important clinical
implications. In particular, LXR-dependent upregula-
tion of SREBP1c potentially limits the usefulness of
LXR agonists to improve cholesterol metabolism, as the
resulting induction of lipogenic programs could lead to
undesirable effects, such as nonalcoholic fatty liver
disease (NAFLD), a condition that has risen to epidemic
proportions in recent years (20). Thus, understanding
how LXR-dependent activation of SREBP1c occurs and
its functional interaction with other pathways control-
ling lipid homeostasis such as PI3K-mTOR signaling are
key open questions.
Oxysterols are a family of metabolites that originate
from an oxygenation reaction of cholesterol. Some
oxysterols are signaling molecules involved in a wide
range of physiological processes controlling cholesterol,
glucose, and lipid metabolisms (21). Levels of oxysterols
are known to change in pathological situations such as
obesity, atherosclerosis, and Alzheimer's disease (22, 23).
A subset of oxysterols function as endogenous LXR
ligands and were shown to activate LXRα-dependent
gene expression in vitro, including those bearing hy-
droxyl groups in positions 4, 7, 20, 22, 24, 25, and 27 on
the cholesterol backbone (4, 24, 25). Interestingly,
although these oxysterols are considered bona fide
LXR activators, none is known to activate SREBP1c and
its downstream lipogenic programs, whereas several
oxysterols have been shown to promote LXR-
dependent cholesterol efflux. In contrast, synthetic
LXR ligands including T0901317 and GW3965 can
induce both cholesterol efflux and SREBP1c-
dependent DNL (18, 19). This leads to the question of
whether DNL is a physiologically relevant LXR-
dependent response, and if so, the identity of the
endogenous ligand that triggers LXR-dependent
SREBP1c expression.
Here we identify 4β-hydroxycholesterol (HC) (4β-
HC) as an LXR activator that selectively triggers
SREBP1c activation and de novo fatty acid and triglyc-
eride synthesis. 4β-HC promoted the expression and
proteolytic processing of SREBP1c but not of the
related steroidogenic factor SREBP2, thus triggering de
novo synthesis of fatty acids but not cholesterol. In
primary mouse hepatocytes, 4β-HC additively enhance
insulin action in promoting SREBP1c expression and
activation, leading to increased triglyceride synthesis
and storage. Thus, 4β-HC may be a novel lipogenic
factor that can shift lipid homeostasis toward triglyc-
eride accumulation via regulation on SREBP1c.
RESULTS
4β-HC is a unique oxysterol that drives SREBP1c
gene expression
To identify oxysterol ligands that could promote
SREBP1c expression, we treated liver
carcinoma–derived Huh7 cells with a panel of oxy-
sterols selected among the most abundant in the
bloodstream, including 4β-, 7β-, 19-, 20-, 24(S)-, 25-, and
27-HC. By quantitative PCR, several oxysterols previ-
ously identified as LXR activators, including 4β-HC, 7β-
HC, 24(S)-HC and 25-HC, induced the expression of a
canonical LXR target gene, ABCA1, with variable po-
tency (Fig. 1A). In contrast, 4β-HC was the only oxy-
sterol to induce significant upregulation of the
SREBP1c transcript (Fig. 1B). A dose-response compari-
son between 4β-HC and 24(S)-HC showed that 24(S)-HC
is a more potent activator than 4β-HC toward ABCA1
(Fig. 1C) and another canonical LXR gene target, ABCG1
(Fig. 1D). Conversely, 4β-HC activated SREBP1c, more
potently than 24(S)-HC (Fig. 1E). 4β-HC–mediated in-
duction of the SREBP1c gene was enantioselective, as the
nonnatural enantiomer of 4β-HC (ent-4HC) was unable
to induce SREBP1c mRNA expression even at the
highest concentration used (20 μM) (Fig. 1F). These data
suggest that SREBP1c induction depends on unique
structural features of 4β-HC.
4β-HC induces expression and activation of SREBP1
but not SREBP2
Oxysterols such as 25- and 27-HC suppress SREBP1
and SREBP2 activation by blocking their trafficking to
the Golgi, where proteolytic processing of the SREBPs
to the mature nuclear form occurs (26, 27).
In contrast to these oxysterols, 4β-HC significantly
increased SREBP1c mRNA levels (Fig. 2A) and protein
levels in a cycloheximide-sensitive manner (Fig. 2B).
However, 4β-HC did not increase either mRNA or
protein levels of SREBP2 (Fig. 2A, B). In keeping with
the increased total levels of SREBP1c, 4β-HC increases
both cytosolic and nuclear forms of SREBP1 in a dose-
dependent manner, whereas levels of cytoplasmic or
nuclear SREBP2 protein levels did not change (Fig. 2C).
Consistent with previous reports (26, 27) and in contrast
to 4β-HC, 25-HC reduced the nuclear forms of both
SREBP1 and SREBP2, thereby causing the accumulation





























































































































































































Fig. 1. 4β-HC is a unique LXR ligand that drives SREBP1c expression. A: Oxysterol screen for LXR target gene expression. Huh7
cells were treated with indicated oxysterols (20 μM) in 24-h time course. ABCA1 mRNA levels or (B) SREBP1c mRNA level were
measured by RT-PCR (N = 3). C: Dose-response curves of 4β-HC and 24-HC in Huh7 cells were treated for 24 h. mRNA levels of
ABCA1, (D) ABCG1, and (E) SREBP1c were measured by RT-PCR. Line plotted by nonlinear fit (N = 3). E: SREBP1c induction by 4β-
HC is stereospecific. Huh7 cells were treated with 4β-HC or an enantiomer of 4β-HC (ent-4HC) for 24 h in the indicated concen-
tration (N = 3). Bars are the mean + SD. Statistical significance calculated by one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001. NS, not significant; 4β-HC, 4β-hydroxycholesterol.
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of the unprocessed cytoplasmic form of both proteins
but without transcriptional upregulation (Fig. 1B).
These data suggest that, unlike other oxysterols that
function as inhibitors of both SREBP1c and SREBP2,
4β-HC is a specific inducer of SREBP1c expression and
activation.
4β-HC induce lipogenic programs through the LXRs
Along with other oxysterols, 4β-HC was previously
shown to activate LXRα-dependent transcription in
luciferase assays in vitro, supporting its role as a puta-
tive LXR ligand (4, 28). In turn, the LXR transcrip-
tionally activates SREBP1c by directly binding to its
promoter region (6). Combining these observations, we
thus hypothesized that 4β-HC may transcriptionally
activate SREBP1c and its downstream lipogenic pro-
grams via the LXR. Consistent with this possibility,
cotreating cells with 4β-HC together with an LXR
antagonist (GSK-2033) abolished 4β-HC–dependent in-
duction of SREBP1c gene expression (Fig. 3A).
The effect of 4β-HC on SREBP1c induction was
additive with an RXR ligand, 9-cis-retinoic acid.
Moreover, coincubation of 4β-HC with the LXR
agonist, GW3965, used at concentrations that activate
the LXR maximally, caused no additional increase in
SREBP1c expression over GW3965 alone (Fig. 3A).
siRNA-mediated knockdown of either the LXRα or
LXRβ (both of which are expressed in Huh7 cells)
largely abolished 4β-HC–dependent SREBP1c mRNA
expression (Fig. 3B). Interestingly, we noticed that 4β-
HC treatment increased LXRα protein levels, a stabi-
lizing effect observed for other established LXR li-
gands (29) (Fig. 3C). Together, and combined with
previous reports these data support the hypothesis
that 4β-HC induces SREBP1c gene expression by




































































Fig. 2. 4β-HC induces expression and activation of SREBP1 but not SREBP2. A: 4β-HC increases SREBP1 protein expression. Huh7
cells were treated with 20 μM 4β-HC and a translation inhibitor, cycloheximide (CHX), for 4 h followed by measurement of SREBP1
and SREBP2 mRNA (N = 3) and (B) protein level (N = 1). C: 4β-HC increases SREBP1 cytosolic and nuclear levels while not affecting
SREBP2. Huh7 cells were treated with 4β-HC or 25-HC for 24 h followed cytosolic-nuclear fractionation to measure protein level of
SREBP1 and SREBP2 cytoplasmic and nuclear levels (N = 1). Asterisk denotes unspecific band in SREBP2 nuclear blot. Bars are the
mean + SD. Statistical significance calculated by one-way ANOVA. ****P < 0.0001. Cyto, cytosolic; Nuc, nuclear; 4β-HC, 4β-
hydroxycholesterol.
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We next compared the ability of 4β-HC to induce
SREBP1c-dependent lipogenic programs with that of
the LXR agonist, GW3965. Fatty acid synthase (FASN),
Stearoyl-CoA desaturase (SCD1) and Lipin1 (LPIN1) are
validated SREBP1c downstream targets in Huh7 cells
(30, 31). Treatment with either 4β-HC or GW3965
significantly increases the expression of these genes
(Fig. 3D). In contrast, 24-HC, another putative LXR
ligand that failed to induce SREBP1c in our hands
(Fig. 1B, E), had minimal or no effect on these SREBP1c
target genes (Fig. 3D).
Previous work had shown that GW3965 induces
FASN to a greater extent than the 1.6-fold we observed
in Huh7 (32). Huh7, a hepatocellular carcinoma line, is
known to hyperactivated DNL to supply membranal
lipids required for rapid division and growth (33, 34).
We speculate that the modest increase in FASN by
GW3965 or 4β-HC is due to already elevated baseline
expression that cannot be increased much further. To
further substantiate the prolipogenic effect of 4β-HC,
we directly measured DNL by C13 incorporation into
triglycerides using LC/MS. Similarly to lipogenic gene
induction, both GW3965 and 4β-HC had a modest but
statistically significant 1.5-fold increase in C13-labeled
C16:C16:C16 TAG, or trending toward significance for
C16:C18:C16 TAG, whereas 24-HC caused no significant
change (Fig. 3E). Combined, these data suggest that the
prolipogenic action of 4β-HC is comparable, in mech-
anism and potency, to known LXR agonists.
4β-HC induces lipid-droplet formation and
triglyceride accumulation
In keeping with the ability of 4β-HC to upregulate
fatty acid biosynthetic genes via SREBP1c, treating
Huh7 cells with 4β-HC (but not with its unnatural
enantiomer, ent-4HC) for 72 h resulted in marked
accumulation of lipid droplets (LDs), as revealed by
















































































































































































































































































Fig. 3. 4β-HC induces lipogenic programs through the LXRs. A: 4β-HC interacts with LXR and RXR agonists and antagonists like
an LXR ligand. Huh7 cells were treated with 20 μM 4β-HC, RXR agonist, 9-cis-retinoic acid (9-RA), LXR antagonist (GSK-2033), and
LXR agonist (GW3965). For convenience, agonists are marked in green and antagonists are marked in red (N = 3). B: LXRα and
LXRβ are required for SREBP1c induction by 4β-HC in Huh7 cells. Knockdown of LXRα or LXRβ by siRNA for 72 h followed by
treatment with 5 μM 4β-HC for 24 h followed by RT-PCR of SREBP1c. (N = 3). C: Knockdown efficiency was evaluated by mea-
surement of LXRα and LXRβ protein levels (N = 3). D: 4β-HC induction of lipogenic genes. Huh7 cells were treated for 24 h with 4β-
HC, 24-HC, or LXR agonist (GW3965) followed by mRNA measurement of fatty acid synthase (FASN), stearoyl-CoA desaturase 1
(SCD1), and lipin1 (LPIN1) (N = 3). E: 4β-HC increases de novo lipogenesis. Huh7 cells were treated for 24 h with 5 μM 4β-HC, 24-HC,
or LXR agonist (GW3965) with media containing C13 glucose followed by lipid extraction. C13 incorporation into TAGs was
measured via LC/MS (N = 5). The asterisk denotes an unspecific band in the LXRα blot. Bars are the mean + SD. Statistical sig-
nificance was calculated by one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 4β-HC, 4β-hydroxycholesterol; 24-HC,
24-hydroxycholesterol.
















































































































































Fig. 4. 4β-HC induces lipid-droplet formation and triglyceride accumulation. A: 4β-HC increases the lipid droplet size and number.
Huh7 cells were treated with 5 μM 4β-HC with indicated drugs for 72 h followed staining with lipid droplet dye, BODIPY 493/503,
and visualization by confocal microscopy and (B) quantified using ImageJ (N = 3). C: 4β-HC increases triglycerides (TAG) levels.
Huh7 cells were treat as (C) followed by measurement of triglycerides, total cholesterol, and protein levels using commercial kits (N =
3). D: 4β-HC increases lipid droplet in the mouse liver. Mice were fed normal chew with either vehicle 50 mg/kg/day 4β-HC or
10 mg/kg/day GW3965 for 5 days. Liver samples were fixed and stained with BODIPY 493/503 and DAPI to observe lipid droplet
and nuclei ultrastructure (N = 3). E: 4β-HC increases triglycerides (TAG) levels in the mouse liver treated as above, followed by
measurement of triglycerides, total cholesterol, and protein levels using commercial kits (N = 3). For convenience, agonists are
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(Fig. 4A, B). LD accumulation induced by 4β-HC was
suppressed by simultaneous treatment with a FASN
inhibitor, TVB-3166, or with the LXR inhibitor GSK-
2033. Measurement of triglyceride content in cell ex-
tracts confirmed the ability of 4β-HC to induce tri-
glyceride accumulation, albeit with lower potency than
the LXR agonist GW3965, whereas cholesterol levels
remained unchanged (Fig. 4C). Consistent with the
BODIPY staining, both LXR and FASN inhibitors hin-
dered 4β-HC–induced triglyceride accumulation
(Fig. 4C). Moreover, as seen with SREBP1c induction, the
ent-4HC failed to induce triglyceride accumulation
(Fig. 4C). Thus, 4β-HC is sufficient to induce the for-
mation of triglyceride-containing LDs in an LXR- and
FASN-dependent manner in cell culture.
Next, we tested the effect of 4β-HC on in vivo lipo-
genesis by feeding mice a normal diet supplemented
with either 4β-HC or GW3965. After 7 days, the livers
were harvested, LDs were assessed by BODIPY staining,
and the liver lipid content (normalized to protein mass)
was measured. Consistent with the results in Huh7 cells,
4β-HC significantly increased the size and number of
LDs in liver sections (Fig. 4D) and liver triglyceride
content (Fig. 4E), albeit with lower potency than the
synthetic LXR agonist, GW3965. Collectively, these data
suggest that 4β-HC is a prolipogenic factor that can
increase liver lipid content in vivo.
4β-HC acts in parallel to insulin-PI3K signaling to
drive SREBP1c expression
Insulin is a key hormone that drives SREBP1c tran-
scription, proteolytic processing, and DNL in the post-
prandial state. Insulin regulates SREBP1c transcription
via poorly understood mechanisms, which include AKT-
dependent transcriptional downregulation of Insig-2a,
the ER-retention factor that blocks translocation of
SREBP cleavage-activating protein-SREBP1c to the Golgi
(35, 36). The LXR was shown to be required for insulin-
dependent activation on SREBP1c (37), but whether and
how insulin activates LXR is not understood.
To interrogate the relationship between 4β-HC and
insulin signaling in driving SREBP1c transcription and
processing, we used an insulin-responsive primary
mouse hepatocyte (38). In these cells, stimulation with
either 4β-HC or insulin alone increased the mRNA
levels of SREBP1c, while combined 4β-HC and insulin
increased SREBP1c mRNA levels additively [as previ-
ously shown for LXR agonists (37)] (Fig. 5A).
Interestingly, treatment with PI3K or mTORC1
inhibitors abolished SREBP1c induction by both
insulin and 4β-HC (Fig. 5A), raising the possibility of a
‘coincidence detection’ model, in which a minimal
amount of both insulin-PI3K-mTORC1 and 4β-HC
signaling must be present for SREBP1c induction to
occur.
Similar to their effects on transcriptional induction,
insulin and 4β-HC stimulated proteolytic processing of
SREBP1c in an additive manner (Fig. 5B). 4β-HC did not
affect AKT phosphorylation significantly, suggesting
that insulin-PI3K-AKT and 4β-HC signaling act in
parallel and converge at the level of the SREBP1 gene
promoter (Fig. 5B and supplemental Fig. 1A).
Consistent with previous reports, we also detected a
marked decrease in Insig-2a mRNA in insulin-
stimulated hepatocytes (Fig. 5C). In contrast, 4β-HC
caused a mild increase of Insig-2a mRNA levels, and
combined insulin and 4β-HC was similar to insulin
alone, suggesting Insig-2a downregulation is not
required for 4β-HC–dependent SREBP1c activation
(Fig. 5C).
To further probe possible connections between
insulin-PI3K and 4β-HC-LXR signaling, we tested
whether insulin signaling promotes 4β-HC synthesis.
Previous reports had shown that in humans, 4β-HC has
a very slow kinetics, with an extremely long half-life in
plasma (60 h) (39). Pharmacological induction of the
main 4β-HC–synthesizing enzyme, cytochrome P450
3A, doubles 4β-HC concentration in human plasma in
8 days (40), a very different pattern from insulin, which
peaks within 1–2 h after a meal and drops in between.
On the other hand, in vitro work in primary rat hepa-
tocytes led to the hypothesis that insulin signaling may
produce an unknown LXR ligand that, in turn, induces
SREBP1c (37). To test the possibility of insulin-
dependent 4β-HC production, we compared 4β-HC
levels in the liver of mice that were either fasted or
refed. Although mice that were refed showed signifi-
cant induction of SREBP1c transcription, consistent
with SREBP1c regulation by insulin (Fig. 5D), the levels
of 4β-HC did not increase accordingly in the liver
(Fig. 5E) or serum (Supplemental Fig. 1B). Collectively,
these data suggest that insulin does not induce 4β-HC
production according to fasting/feeding cycles and
that 4β-HC most likely acts in parallel to insulin-PI3K
signaling in driving SREBP1c transcription and
SREBP1c-dependent DNL (Fig. 5F).
DISCUSSION
Here we identify 4β-HC as a unique oxysterol that
activates SREBP1c expression and promotes lipogenic
gene programs, resulting in induction of fatty acid
biosynthesis and cellular accumulation of triglycerides
in LDs both in cell culture and in vivo. Our results are
most consistent with a model in which 4β-HC acts in
parallel to insulin-PI3K-mTOR signaling, and the two
marked in green and antagonists are marked in red. Bars are the mean + SD. Statistical significance calculated by one-way
ANOVA.*P < 0.05, **P < 0.01, ****P < 0.0001. ent-4HC, stereo enantiomer-4HC, FASNi, TVB-3166; LXRi, GSK-2033; 4β-HC, 4β-
hydroxycholesterol.





























































































































































Fig. 5. 4β-HC acts in parallel to insulin-PI3K signaling to drive SREBP1c expression. A: SREBP1c transcription is additive by 4β-HC and
insulin. Primary hepatocytes were treated overnight with vehicle or 5 μM 4β-HC followed with 6 h stimulation with combinations of
insulin, PI3K inhibitor (LY294002), or rapamycin. The SREBP1c mRNA level was measured by RT-PCR (N = 4). B: 4β-HC and insulin
have an additive effect on SREBP1c expression and nuclear processing. Primary hepatocytes were treated overnight with vehicle or 4β-
HC followed by addition of insulin for 40 min. Proteins were extracted and SREBP1 and AKT protein levels were measured (N = 2). C:
Primary hepatocytes were treated with 4β-HC and insulin as described in (A) followed by RT-PCRmeasurement of Insig-2a mRNA level
(N = 4). D: Insulin does not induce 4β-HC synthesis. Mice were fasted for 16 h and then refed for 4 h, followed by liver extraction and RT-
PCR for SREBP1c mRNA level (N = 4) and (E) 4β-HC levels by MS (N = 5). F: Model; the 4β-HC-LXR pathway acts in parallel to the
insulin-PI3K pathway to drive SREBP1c expression in an additive fashion. **P < 0.01, ***P < 0.001, ****P < 0.0001.
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pathways have additive effects on SREBP1c activation.
A simple mechanism that explains the additive effect is
that the SREBP1c promoter contains both an LXR-
binding element and an SREBP-binding element and
that transcription can be stimulated by the two tran-
scription factors independently (41). However, the
observation that inhibition of PI3K-AKT signaling also
blunts 4β-HC–dependent SREBP1 induction (Fig. 5A)
points to a possible ‘coincidence detection’ model,
where at least some signaling by one input (i.e., insulin)
has to be present for the other input (4β-HC) to be
effective, and vice versa. From a temporal standpoint,
4β-HC kinetics suggest that it stimulates SREBP1c
expression in a chronic manner, whereas insulin acts
acutely in the postprandial state.
A recent publication by Salonurmi et al. (42) showed
that 4β-HC induces cholesterol efflux from periph-
eral mononuclear cells in vivo via transcriptional
upregulation of ABCA1 and concomitant suppression
of influx transporters. In our hands, 4β-HC did not
induce ABCA1 expression in primary hepatocytes
(supplemental Fig. 1C), whereas its induction was
observed in Huh7 cells. Thus, 4β-HC–dependent
regulation of cholesterol efflux versus DNL may be
cell type specific and tied to different physiological
settings.
Several groups using different animal models (mice,
rats, rabbits, and swine) had all observed that 4β-HC
levels increase when animals are fed a high cholesterol
diet (43–46), whereas a high-fat but with low-cholesterol
diet reduces 4β-HC levels in mice (47). Dietary choles-
terol was shown to increase SREBP1c expression in an
LXR-dependent manner (6, 9). Furthermore, geneti-
cally disrupting hepatic cholesterol synthesis through
SREBP2 KO also causes SREBP1c downregulation, which
can be rescued by an LXR agonist (48). This study also
determined that 4β-HC levels are decreases in young
SREBP2-null mice, defining a correlation between
SREBP2-dependent cholesterol synthesis, 4β-HC levels,
and SREBP1c expression. Together with this published
literature, our results strongly suggest that 4β-HC may
be the cholesterol-derived molecule that induces
SREBP1c activation via the LXR.
An important question is why 4β-HC is the sole
oxysterol ligand of LXRs to activate SREBP1 expression
in our hands. Several possibilities can be envisioned.
The LXR-RXR heterodimer can recruit coactivators
(PGC-1α, TRRAP, ACS-2, p300, SRC-1) and corepressors
(NCoR, SMRT) to the promoters of target genes in a
ligand-dependent manner (49–53), but whether all LXR
ligands are equally effective in recruiting specific
combinations of cofactors is unclear. Supporting this
model was an observation in macrophages that the
ability of the LXR to recruit RNA polymerase II to
SREBP1c promoter requires a specific LXR ligand, while
recruitment of RNA polymerase II to the ABCA1 pro-
moter is more promiscuous (29). Thus, 4β-HC may be
able to direct a unique set of coactivators and RNA
polymerase II to the SREBP1c promoter, resulting in its
activation.
Consistent with previous reports, the synthetic LXR
agonist GW3965 was also able to trigger SREBP1 expres-
sion (18, 19). Synthetic LXR agonists are generally more
potent than natural LXR ligands, possibly reflecting
higher affinity for the ligand-binding site of theLXR.By
analogy, 4β-HCmaybind to theLXRwithhigher affinity
than other oxysterol ligands. In turn, higher affinitymay
translate into longer residence time on the SREBP1c
promoter DNA, a possible prerequisite for its efficient
activation.
Our data point to the importance of the enzyme that
produces 4β-HC, Cyp3A4 (Cyp3A11 in mice) (54), as a
crucial regulator of lipogenesis. Consistent with that,
several groups have reported that increased Cyp3A4
expression by overexpressing its activator, pregnane X
receptor, correlated with increases in lipogenic gene
expression and liver triglyceride levels (55, 56).
Conversely, decreased Cyp3A4 expression (57) or its
pharmacological inhibition (58) was associated with
lower lipogenic gene expression and liver triglyceride
levels. Taken together, these data suggest that Cyp3A4
and 4β-HC may regulate diet-induced lipogenic genes
and liver triglyceride levels.
From a more clinical perspective, 4β-HC might have
an aggravating effect on the development of NAFLD.
NAFLD is characterized by elevated liver triglycerides
not due to alcohol consumption or any other known
causes (59). Elevated triglyceride levels are associated
with LXR and SREBP1c upregulation in NAFLD (60).
Patients with NAFLD show a significant increase in 4β-
HC plasma levels compared with healthy patients (61).
Thus, it is plausible that elevated 4β-HC levels could be
an unrecognized driver of triglyceride accumulation in
NAFLD. It would be interesting to determine the effect
of pharmacologic Cyp3A4 inhibition on disease pro-
gression in patients with NAFLD.
In conclusion, this work highlights a role for 4β-HC,
which was long viewed as an ‘orphan’ oxysterol, in
regulating lipid metabolism in the liver together with
insulin. Future work, dissecting the role of 4β-HC in
other organs and in different pathological settings, will
provide a full picture on the function and significance
of this highly abundant oxysterol.
MATERIALS AND METHODS
Materials
Reagents were purchased from the following sources. An-
tibodies used are as follows: SREBP1 (2A4, Santa Cruz
Biotechnology), SREBP2 (30682, Abcam), LXRα (PP-PPZ0412-
00, R&D systems), LXRβ (K8917, R&D systems), phospho-T308
AKT (C31E5E), AKT (11E7) (Cell Signaling Technology).
Drugs used are as follows: Cycloheximide (Cell Signaling
Technology) was used at 10 μg/ml. 9-cis-retinoic acid (Sigma)
was used at 50 μM. The LXR antagonist GSK-2033 (Axon
Medchem) was used at 500 nM. The LXR agonist GW3965
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(Fisher Scientific) was used at 500 nM. PI3K inhibitor,
LY294002 (Cell Signaling Technology), was used at 10 μM.
Rapamycin was used at 100 nM and received as a gift from
David Sabatini. Methyl-beta-cyclodextrin was purchased from
Sigma. All sterols except for custom-synthesized ent-4β-HC
(see below) were purchased from Steraloids. C13 glucose was
purchased from Cambridge Isotope Laboratories.
Sterol: methyl-beta-cyclodextrin precomplexing
All sterols were made to 50 mM stocks in ethanol. To
deliver the sterols to cells, 1.25 mM sterol was complexed with
25-mM methyl-beta-cyclodextrin and vortexed until the so-
lution was clear. Sterols were added to the media in an indi-
cated concentration and incubation time. Control samples
were treated by adding the same volume of ethanol to
methyl-beta-cyclodextrin, which then was delivered to cells in
the same corresponding volume.
Cell culture
Huh7 cells were maintained on DMEM (5 g/l glucose +
glutamine, Gibco) supplemented with 10% FBS (VMR) and p/s
(Gibco). Lipid-depleted serum (LDS) was made as described (62).
For assays, on day one; 105 cells were plates in 6 cm plates. On
day 2, media was changed to 1% LDS and 1 g/l glucose DMEM.
On day 3; plates were spiked with precomplexed sterols for
indicated times, concentrations, and additional compounds.
Primary mouse hepatocytes were purchased from the
UCSF liver center. The isolation protocol is based on the
study by Li, Brown, and Goldstein (63) and adjusted in the
following manner. Mice were fasted overnight before
isolation. Hepatocytes were isolated by the perfusion pro-
tocol (64) and plated at density of 7 × 105/well on 6-well
collagen-coated plates (Corning) in DMEM supplemented
with 10% FBS. Once cells adhere, the media was replaced to
Medium 199 (GIBCO) containing 100 nM dexamethasone
(Sigma), 100 nM 3,3,5-triiodo-L-thyronine (T3, Sigma), and
Insulin-Transferrin-Selenium (Gibco). Next day, the same
media was used without Insulin-transferrin-Selenium to
assay insulin, 4β-HC, and inhibitors at indicated times and
concentrations.
Real-time PCR analysis for gene expression
RNA was extracted using the RNeasy kit (Qiagen). One
microgram of RNA was reverse-transcribed using Super
Script III (Invitrogen). Quantitative PCR was performed using
Ssoadvanced (Bio-Rad) in StepOnePlus (ABI). The list of
primers is in Table 1.
Protein extraction and Western blot
Cells were harvested with the RIPA buffer supplemented
with Phosphatase inhibitor and protease inhibitor (10 mM Tris
Cl (pH 8.0), 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxy-
cholate, 0.1% SDS, 140mMNaCl, 10mMNa-PPi, 10mMNa-Beta-
glycerophosphate), sonicated with Bioruptor (Diagenode), and
normalized using the BCA kit (Thermo Scientific).
Knockdown using siRNA
siRNA ON-TARGET plus smart pool against LXRα (cat# L-
003413-00-0005), LXRβ (cat# L-003412-02-0005), or non-
targeted siRNA ON-TARGETplus Non-targeting Pool (cat#
D-001810-10-05) was purchased from Dharmacon. Five
micromolar siRNA was mixed with 5 μl Lipofectamine
RNAiMAX (Life Technologies) in Opti-MEM (Gibco). siRNA
is added to preplated Huh7 (105 cells/6 cm plate) in regular
media without penicillin streptomycin for 5 h followed by
replacement to regular media for 72 h.
LD microscopy
Huh7 were plated on a coverslip coated with fibronectin
(Corning) and treated as indicated with sterols and drugs. Cells
were fixed with paraformaldehyde and stained with 1 μg/ml
BODIPY 493/503 for 1 h. Coverslips were mounted with VEC-
TASHIELD with DAPI (Vector Laboratories) and imaged on a
spinning disk confocal system (Andor Revolution on a Nikon
EclipseTimicroscope). TheBODIPY signal wasmeasuredusing
ImageJ and normalized by the number of nuclei.
Triglyceride and cholesterol measurements
Liver samples were powdered with a pestle and mortar
and lysed in the RIPA buffer. Huh7 cells were also harvested
in the RIPA buffer. Five microliters of the samples was used
to measure triglyceride using Triglyceride Infinity (Thermo
Fisher) or cholesterol using the Amplex red cholesterol
measuring kit (Invitrogen) in a clear 96-well sample. The
BCA kit (Thermo Scientific) was used for normalization of
the protein level. Absorbance and fluorescence were
measured by the PerkinElmer Envision Multilabel plate
reader.
C13 incorporation into triglycerides
Huh7 cells were seeded at 200K per 6-cm plates. The next
day, DMEM media with glutamine, containing 5 mM C13
glucose (Cambridge Isotope Laboratories) and 1% LDS
including oxysterols and the LXR agonist were added for
24 h. C12 glucose–treated plates were used as reference. Cells
TABLE 1. RT-PCR primers
Gene Species Forward Reverse
TBP Human TTGTACCGCAGCTGCAAAAT TATATTCGGCGTTTCGGGCA
SREBP1c Human GCGCCTTGACAGGTGAAGTC GCCAGGGAAGTCACTGTCTTG
FASN Human CTTCAAGGAGCAAGGCGTGA ACTGGTACAACGAGCGGATG
SCD1 Human TCTAGCTCCTATACCACCACCA TCGTCTCCAACTTATCTCCTCC
ABCA1 Human TGTTCGCGGCCCTCAT CGAGATATGGTCCGGATTGC
ABCG1 Human TGCAATCTTGTGCCATATTTGA CCAGCCGACTGTTCTGATCA
LPIN1 Human CCAGCCCAATGGAAACCTCC AGGTGCATAGGGATAACTTCCTG
SREBP2 Human GAGCTGGGTGGTCTGGAG TTGCAGCATCTCGTCGATGT
SREBP1C Mouse CGGAAGCTGTCGGGGTAG GTTGTTGATGAGCTGGAGCA
SREBP2 Mouse GCGTTCTGGAGACCATGGA ACAAAGTTGCTCTGAAAACAAATCA
INSIG-2A Mouse TGTGAGCTGGACTAGCTTGCT CCTAAGCCGTAAAACAAAATG
TBP Mouse ACCCTTCACCAATGACTCCTATG ATGATGACTGCAGCAAATCGC
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were washed twice with ice-cold PBS and scraped, and pellets
were snap-frozen and kept in −80◦C for later analysis. Lipid
extraction and analysis by LC/MS was performed as
described (65).
Husbandry and diets
All mouse procedures were performed and approved
under the University of California, Berkeley Animal Care
and Use Committee. Ten-week-old C57BL/6J male mice
were purchased from the Jackson Laboratory and housed
for one week in our facility under standard conditions
before experiments were performed. Free access to water
and chow (Lab Diets, #3038) was provided throughout this
acclimation period. Afterward, mice were placed on a diet
with 50 mg/kg/day 4β-HC or LXR agonist GW3965
10 mg/kg/day for 7 days. Powdered 10% by kCal fat diet
(Research Diets Inc. #D12450J) was used as the base of
each treatment food, forming pellets that were dried
overnight at room temperature in a laminar flow hood.
After 7 days, mice were euthanized using CO2 and cer-
vical dislocation.
Cryosectioning and fluorescent histochemistry
Liver samples were fixed using 4% (v/v) paraformaldehyde
overnight at 4◦C. The next day, samples were cryopreserved
using sterile-filtered 30% sucrose (w/v) in dulbecco’s phos-
phate buffered saline (DPBS) (Gibco, 14190-144). After 3 days,
each sample was placed in a 1:1 30% sucrose:Neg-50 (Richard-
Allan Scientific) solution and incubated overnight at 4◦C. The
samples were frozen on dry ice using undiluted Neg-50
at −50◦C and stored at −80◦C until sectioning. Sequential
20 μM thick sections were obtained from each sample using a
Leica CM3050S cryostat.
For nuclei and LD labeling, sectioned tissue was washed three
times at room temperature in DPBS for 5 min each. Afterward,
DPBS containing 10 μM BODIPY (Invitrogen, #D3922) was
placed on the samples and incubated for 30 min at room tem-
perature in the dark. Next, the slides were washed with DPBS
twice before incubating in DPBS containing 5 μg/ml DAPI
(Invitrogen, D1306) for 10 min at room temperature in the dark.
After DAPI staining, the slides were washed three times inDPBS
for 5min each before beingmounted using SlowFadeDiamond
antifade (Invitrogen, #S36972) and sealing with nail polish
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confocalmicroscope. Images were developed using the IMARIS
(Bitplane) image analysis software suite.
Synthesis of ent-4β-HC
ent-steroid 2. ent-Testosterone (1) was prepared as described
previously [(66); see also references therein]. To a solution of
ent-testosterone (1, 3.8 g, 13.2 mmol) in acetic anhydride (80 ml)
was added NaI (7.92 g, 52 mmol) and trimethylsilyl chloride
(5.8 ml, 52 mmol) at 0◦C under N2. After addition, the reaction
was allowed to warm to room temperature for 2 h. The re-
action was added to Et3N (40 ml) in diethyl ether (100 ml). The
ether solution was washed with brine (50 ml × 4) and aqueous
NaHCO3 (50 ml × 2) and dried over Na2SO4. After filtration,
the solvent was removed under reduced pressure and the
residue was purified by flash column chromatography (silica
gel eluted with 25% ethyl acetate (EtOAc) in hexanes) to give
ent-steroid 2 (3.05 g, 70%): 1H NMR (400 MHz, CDCl3) δ
5.33–5.32 (m, 1H), 4.60 (t, J = 8.3 Hz, 1H), 3.52–3.47 (m, 1H),
2.30–0.90 (m), 2.02 (s, 3H), 1.00 (s, 3H), 0.79 (s, 3H); 13C NMR
(100 MHz, CDCl3) δ 171.2, 140.9, 121.1, 82.7, 71.5, 51.0, 50.0, 42.3,
42.2, 37.2, 36.7, 36.5, 31.6, 31.5, 31.4, 27.4, 23.5, 21.1, 20.5, 19.3, 11.8.
ent-steroid 3. ent-Steroid 2 (3.05 g, 4.04 mmol) was dissolved
in CH2Cl2 (50 ml) and cooled to 0◦C. (i-Pr)2EtN (3.0 ml) and
ClCH2OMe (1.35 ml, 18.0 mmol) were added, and the reaction
was stirred at room temperature for 16 h. The reaction was
made basic by adding aqueous NaHCO3 solution, and the
product was extracted into CH2Cl2. The combined extracts
were washed with brine, dried over Na2SO4, filtered, and
solvent removed to give a viscous liquid that was purified by
flash column chromatography (silica gel eluted with 10%
EtOAc in hexanes) to give ent-steroid 3 as a colorless liquid
(2.65 g, 77%): 1H NMR (400 MHz, CDCl3) δ 5.33–5.32 (m, 1H),
4.65 (s, 2H), 4.59 (t, J = 8.2 Hz, 1H), 3.39–3.35 (m, 1H), 3.34 (s, 3H),
2.35–0.89 (m), 2.01 (s, 3H), 0.99 (s, 3H), 0.78 (s, 3H); 13C NMR
(100 MHz, CDCl3) δ 171.0, 140.7, 121.2, 94.6, 82.6, 76.7, 55.0, 50.9,
50.0, 42.3, 39.4, 37.1, 36.7, 31.6, 31.4, 28.8, 27.4, 23.5, 21.0, 20.4, 19.3,
11.8.
ent-steroid 4. To a solution of ent-steroid 3 (2.65 g,
7.05 mmol) in methanol (60 ml), K2CO3 (4.0 g) was added at
room temperature. The mixture was refluxed for 16 h.
Methanol was removed under reduced pressure, and the
residue was purified by flash column chromatography (silica
gel eluted with 25% EtOAc in hexanes) to give ent-steroid 4
(2.31 g, 99%): 1H NMR (400 MHz, CDCl3) δ 5.32–5.30 (m, 1H),
4.64 (s, 2H), 3.61 ( t, J = 8.6 Hz, 1H), 3.40–3.34 (m, 1H), 3.33 (s, 3H),
2.31–0.87 (m), 0.95 (s, 3H), 0.72 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 140.7, 121.3, 94.5, 81.6, 76.7, 55.0, 51.2, 50.2, 42.6, 39.4,
37.2, 36.7, 36.5, 31.8, 31.4, 30.3, 28.8, 23.3, 20.5, 19.3, 10.9.
ent-steroid 5. To a solution of ent-steroid 4 (1.5 g, 4.54 mmol)
in CH2Cl2 (60 ml), Dess–Martin periodinane (2.5 g, 6 mmol)
was added at room temperature. After 1 h, water (50 ml) was
added, the product was extracted into CH2Cl2 (150 ml × 3), and
the combined extracts were washed with brine (50 ml × 2).
The organic layer was dried over Na2SO4 and filtered and the
solvents were removed. The residue was purified by flash
column chromatography (silica gel eluted with 10% EtOAc in
hexanes) to give ent-steroid 5 (1.5 g, 100%): 1H NMR (400 MHz,
CDCl3) δ 5.39–5.38 (m, 1H), 4.68 (s, 2H), 3.45–3.38 (m, 1H), 3.37 (s,
3H), 2.49–0.98 (m), 1.03 (s, 3H), 0.88 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 221.0, 140.9, 120.9, 94.7, 76.7, 55.1, 51.7, 50.2, 47.5, 39.5,
37.1, 36.8, 35.8, 31.4, 31.3, 30.8, 28.8, 21.8, 20.3, 19.3, 13.5.
ent-steroid 6. A solution of freshly prepared sodium eth-
oxide (sodium 0.4 g, 15 mmol dissolved in ethanol 15 ml) was
added dropwise slowly to a solution of ent-steroid 5 (1.5 g,
4.54 mmol) and triethyl phosphonoacetate (3.44 g, 15 mmol) in
anhydrous ethanol (25 ml) under N2 while stirring at 35–40◦C.
After addition, the reaction was refluxed for 16 h. After
cooling to room temperature, the ethanol was removed and
the residue was dissolved in ether, which was washed with
water, dried over Na2SO4, and filtered. The solvent was
removed, and the residue was purified by flash column
chromatography (silica gel eluted with 10% EtOAc in hexanes)
to give ent-steroid 6 (1.68 g, 87%): 1H NMR (400 MHz, CDCl3) δ
5.52 (s, 1H), 5.35–5.34 (m, 1H), 4.66 (s, 2H), 4.15–4.09 (m, 2H),
3.43–3.33 (m, 1H), 3.35 (s, 3H), 2.84–2.79 (m, 2H), 2.36–0.93 (m),
1.01 (s, 3H), 0.82 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 176.1, 167.3,
140.7, 121.3, 108.6, 94.6, 76.7, 59.4, 55.1, 53.7, 50.2, 46.0, 39.5, 37.2,
36.8, 35.1, 31.6, 31.5, 30.4, 28.8, 24.4, 20.9, 19.3, 18.2, 14.3.
The reaction sequence reported below that converts
ent-steroid 6 into ent-steroid 16 (ent-VP1-001) is based on that
reported previously for the preparation of the natural
stereoisomer of ent-steroid 16 (67).
Unpurified ent-steroid 7. To a solution of ent-steroid 6 (1.4 g,
3.48 mmol) in EtOAc (150 ml), PtO2 (15 mg) was added at room
temperature. Hydrogenation was carried out under 20 psi for
6 h. The solvent was removed, and the residue was purified by
flash column chromatography (silica gel eluted with 10%
EtOAc in hexanes) to give unpurified ent-steroid 7 (1.4 g,
100%): 1H NMR δ 4.63–4.60 (m, 1H), 4.08–4.03 (m, 2H), 3.48–3.32
(m, 1H), 3.31 (s, 3H), 2.34–0.57 (m), 0.76 (s, 3H), 0.54 (s, 3H); 13C
NMR δ 176.1, 140.7, 121.3, 94.4, 76.2, 60.0, 55.3, 55.0, 54.5, 46.9,
44.9, 42.1, 37.4, 37.0, 35.6, 35.5, 35.3, 35.2, 32.1, 28.7, 28.1, 24.4, 20.9,
14.2, 12.5.
Unpurified ent-steroid 7 contains minor amounts of the ent-
steroid in which the Δ5 double bond has been hydrogenated.
This saturated ent-steroid could not be removed easily by
chromatography on silica gel. To separate the two compounds
chromatographically, ent-steroid 7 was converted first into ent-
steroid 8 and then into ent-steroid 9, which is easily purified.
ent-Steroid 9 was then converted back via ent-steroid 8 into ent-
steroid 7 and then subsequently into ent-steroid 10.
Unpurified ent-steroid 8. Acetyl chloride (2 ml) was slowly
added to unpurified hydrogenation product ent-steroid 7
(1.4 g, 3.48 mmol) in ethanol (30 ml) at room temperature.
After 2 h, water was added and the product was extracted into
CH2Cl2 (100 ml × 2). The combined extracts were dried over
Na2SO4 and filtered, and the solvent was removed under
reduced pressure. The residue was purified by flash column
chromatography (silica gel eluted with 25% EtOAc in hex-
anes) to give unpurified ent-steroid 8 (1.2 g): 1H NMR (400 MHz,
CDCl3) δ 5.35–5.34 (m, 1H), 4.13–4.07 (m, 2H), 3.55–3.47 (m, 1H),
2.38–0.81 (m), 1.10 (s, 3H), 0.61 (s, 3H); 13C NMR (100 MHz, CDCl3)
δ 173.9, 140.8, 121.5, 71.6, 60.1, 55.5, 50.3, 46.8, 42.2, 41.9, 37.3, 37.2,
36.5, 35.2, 31.9, 31.8, 31.6, 28.1, 24.5, 20.8, 19.4, 14.2, 12.4.
ent-steroid 9. To a solution of unpurified ent-steroid 8 (1.2 g,
3.33 mmol) in diethyl ether (100 ml) and acetic acid (5 ml), Br2
in HOAc (3 ml) was added slowly until brown color persisted.
After 5 min, aqueous Na2S2O3 was added and the reaction
became colorless. EtOAc (100 ml) was added, and the EtOAc
solution was washed with aqueous NaHCO3 (50 ml × 2), brine
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(50 ml), and dried over anhydrous Na2SO4. After filtration,
the solvent was removed under reduced pressure, and the
residue was purified by flash column chromatography (silica
gel eluted with 20% EtOAc in hexanes) to give ent-steroid 9
(1.4 g, 81%): 1H NMR (400 MHz, CDCl3) δ 4.82–4.81 (m, 1H),
4.44–4.37 (m, 1H), 4.12–4.06 (m, 2H), 2.72–1.08 (m), 1.43 (s, 3H),
0.62 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 173.8, 89.6, 68.9, 60.1,
56.0, 54.0, 47.6, 46.6, 45.6, 42.2, 42.0, 37.2, 37.0, 36.7, 35.2, 30.9,
30.1, 28.0, 24.2, 21.0, 20.3, 14.2, 12.7.
Purified ent-steroid 8. Zinc dust (6.0 g) was added to a solu-
tion of ent-steroid 9 (1.4 g, 2.7 mmol) in HOAc (20 ml) and
EtOAc (30 ml) at room temperature. After 16 h, the mixture
was filtered through Celite and washed with EtOAc (200 ml).
The solvent was removed under reduced pressure, and the
residue was purified by flash column chromatography (silica
gel eluted with 25% EtOAc in hexanes) to give purified ent-
steroid 8 (925 mg, 95%): 1H NMR (400 MHz, CDCl3) δ 5.26–5.25
(m, 1H), 4.06–4.01 (m, 2H), 3.85 (s, br, 1H), 3.47–3.40 (m, 1H),
2.31–0.73 (m), 0.93 (s, 3H), 0.54 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 173.8, 140.7, 121.1, 71.2, 60.0, 55.4, 50.1, 46.6, 41.9, 41.7,
37.1, 37.0, 36.3, 35.0, 31.7, 31.7, 31.2, 27.9, 24.3, 20.6, 19.2, 14.0, 12.2.
Purified ent-steroid 7. Purified ent-steroid 8 (925 mg,
2.57 mmol) was dissolved in CH2Cl2 (20 ml) and cooled to 0◦C.
(i-Pr)2EtN (1.3 ml, 7.5 mmol) and ClCH2OMe (0.45 ml,
6.0 mmol) were added, and the reaction was stirred at room
temperature for 16 h. The reaction mixture was made basic by
adding aqueous saturated NaHCO3 solution and the product
extracted into CH2Cl2. The combined extracts were washed
with brine, dried over anhydrous Na2SO4, and the solvent
removed to give a viscous liquid that was purified by flash
column chromatography (silica gel eluted with 20% EtOAc in
hexanes) to give purified ent-steroid 7 as a colorless liquid
(1.02 g, 98%): 1H NMR (400 MHz, CDCl3) δ 5.34–5.33 (m, 1H),
4.67 (s, 2H), 4.12 (q, J = 7.0 Hz, 2H), 3.42–3.36 (m, 1H), 3.35 (s, 3H),
2.37–0.80 (m), 1.00 (s, 3H), 0.60 (s, 3H); 13C NMR (CDCl3) δ 173.8,
140.7, 121.5, 94.6, 76.8, 60.0, 55.5, 55.1, 50.3, 46.7, 41.9, 39.5, 37.2,
37.1, 36.7, 35.2, 31.9, 31.8, 28.9, 28.1, 24.5, 20.7, 19.3, 14.2, 12.3.
ent-steroid 10. To a solution of the ent-steroid 7 (202 mg,
0.5 mmol) in tetrahydrofuran (THF) (10 ml), lithium diiso-
propylamide (0.75 ml, 2.0 M in THF, 1.5 mmol) and HMPA
(0.29 ml, 1.65 mmol) were added at –78◦C. After 1 h, 1-bromo-4-
methylpentane (0.44 ml, 3 mmol) was added. After addition,
the reaction was warmed to room temperature for 16 h.
Aqueous NH4Cl was added and extracted with EtOAc
(100 ml × 2), and the combined extracts were dried over
anhydrous Na2SO4. The solvent was removed under reduced
pressure, and the residue was purified by flash column
chromatography (silica gel eluted with 20% EtOAc in hex-
anes) to give ent-steroid 10 (236 mg, 97%): 1H NMR (400 MHz,
CDCl3) δ 5.34–5.33 (m, 1H), 4.67 (s, 2H), 4.13–4.08 (q, J = 7.4 Hz,
2H), 3.41–3.37 (m, 1H), 3.35 (s, 3H), 2.35–0.79 (m), 0.98 (s, 3H), 0.70
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 176.2, 140.7, 121.5, 94.6, 76.9,
59.6, 56.0, 55.1, 52.6, 50.1, 47.4, 41.9, 39.5, 38.8, 37.5, 37.2, 36.7, 32.2,
31.8, 31.7, 28.9, 27.8, 27.0, 25.0, 23.8, 22.7, 22.3, 20.8, 19.3, 14.2, 12.0.
ent-steroid 11. To a solution of ent-steroid 10 (236 mg,
0.5 mmol) in diethyl ether (20 ml), LiAlH4 (2.0 M in diethyl
ether, 4.0 ml, 8.0 mmol) was added at room temperature. After
2 h, water (0.32 ml), 10% of NaOH (0.64 ml), and water (0.96 ml)
were slowly added sequentially. After stirring for 30 min, the
mixture was filtered through Celite and washed with CH2Cl2
(100 ml). The solvent was removed under reduced pressure
and the residue was purified by flash column chromatog-
raphy (silica gel eluted with 25% EtOAc in hexanes) to give ent-
steroid 11 (212 mg, 98%): 1H NMR (400 MHz, CDCl3) δ 5.34–5.33
(m, 1H), 4.66 (s, 2H), 3.71–3.61 (m, 2H), 3.44–3.36 (m, 1H), 3.34 (s,
3H), 2.35–0.88 (m), 0.99 (s, 3H), 0.68 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 140.6, 121.6, 94.6, 76.7, 62.5, 56.6, 55.1, 50.3, 50.1, 42.3,
42.0, 39.5, 39.1, 37.2, 36.6, 31.8, 29.5, 28.8, 27.9, 27.5, 24.1, 24.0, 22.7,
22.5, 21.0, 19.3, 12.1.
ent-steroid 12. To a solution of ent-steroid 11 (212 mg,
0.48 mmol) in CH2Cl2 (10 ml), mesyl chloride (1 mmol, 0.08 ml)
and Et3N (0.28 ml, 2 mmol) were added at 0◦C. After 1 h,
aqueous NH4Cl was added and the product was extracted into
CH2Cl2 (100 ml × 2). The combined extracts were dried over
anhydrous Na2SO4 and filtered and the solvents removed.
The residue was purified by flash column chromatography
(silica gel eluted with 10% EtOAc in hexanes) to give ent-ste-
roid 12 (241 mg, 97%): 1H NMR (400 MHz, CDCl3) δ 5.33–5.32
(m, 1H), 4.66 (s, 2H), 4.36–4.32 (m, 1H), 4.18–4.09 (m, 1H),
3.42–3.37 (m, 1H), 3.34 (s, 3H), 2.97 (s, 3H), 2.34–0.89 (m), 0.98 (s,
3H), 0.69 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 140.6, 121.4, 94.6,
76.8, 70.0, 56.4, 55.1, 50.0, 49.9, 42.0, 39.7, 39.4, 39.2, 39.0, 37.2, 37.1,
36.6, 31.7, 31.6, 29.4, 28.8, 27.7, 27.4, 24.0, 23.4, 22.6, 22.4, 20.9, 19.3,
12.1.
ent-steroid 13. To a solution of ent-steroid 12 (241 mg,
0.46 mmol) in diethyl ether (30 ml), LiAlH4 (2.0 M in diethyl
ether, 4.0 ml, 8.0 mmol) was added at room temperature. After
2 h, water (0.32 ml), 10% of NaOH (0.64 ml), and water (0.96 ml)
were slowly added sequentially. After stirring for 30 min, the
mixture was filtered through Celite and washed with CH2Cl2
(100 ml). The solvent was removed under reduced pressure
and the residue was purified by flash column chromatog-
raphy (silica gel eluted with 10% EtOAc in hexanes) to give ent-
steroid 13 (188 mg, 95%): 1H NMR (400 MHz, CDCl3) δ 5.35–5.34
(m, 1H), 4.68 (s, 2H), 3.46–3.38 (m, 1H), 3.36 (s, 3H), 2.37–0.86 (m),
1.01 (s, 3H), 0.68 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 140.7, 121.7,
94.6, 76.9, 56.7, 56.1, 55.1, 50.1, 42.3, 39.8, 39.5, 39.4, 37.2, 36.7, 36.2,
35.8, 31.9, 31.8, 28.9, 28.2, 28.0, 24.3, 23.8, 22.8, 22.5, 21.0, 19.3, 18.7,
11.8.
ent-steroid 14 (ent-cholesterol). To a solution of ent-steroid 13
(188 mg, 0.44 mmol) in THF (20 ml), 6 N HCl (10 ml) was added
at room temperature. After 4 h, the product was extracted
into CH2Cl2 (100 ml × 2) and the combined extracts were
washed with aqueous NaHCO3 (50 ml × 2), dried over anhy-
drous Na2SO4, and filtered. The solvent was removed under
reduced pressure, and the residue was purified by flash col-
umn chromatography (silica gel eluted with 20% EtOAc in
hexanes) to give ent-steroid 14 (165 mg, 98%); 1H NMR
(400 MHz, CDCl3) δ 5.36–5.35 (m, 1H), 3.57–3.49 (m, 1H),
2.33–0.86 (m), 1.01 (s, 3H), 0.68 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 140.7, 121.7, 71.8, 56.7, 56.1, 50.1, 42.3, 42.2, 39.8, 39.5,
37.2, 36.5, 36.2, 35.8, 31.9(2C), 31.6, 28.2, 28.0, 24.3, 23.8, 22.8, 22.6,
21.1, 19.4, 18.7, 11.8.
ent-steroid 15 (ent-4β-HC). A procedure previously re-
ported to convert cholesterol to 4β-HC was used (68) to
convert ent-cholesterol 14 into ent-4β-HC 15.
To a solution of ent-cholesterol 14 (29 mg, 0.0747 mmol) in
dioxane (5 ml) and water (2 drops), SeO2 (17 mg, 0.15 mmol)
was added at room temperature. The mixture was heated to
90◦C for 16 h. After cooling to room temperature, the solvent
was removed under reduced pressure. The residue was puri-
fied by flash column chromatography (silica gel eluted with
4βHC coordinates cholesterol with fatty acid metabolism 13
30% EtOAc in hexanes) to give ent-4β-HC 15 (17 mg, 58%): mp
169–171◦C; [α]D20 +41.7 (c = 0.12, CHCl3); 1H NMR (400 MHz,
CDCl3) δ 5.69–5.68 (m, 1H), 4.15–4.14 (m, 1H), 3.58–3.55 (m, 1H),
2.20–0.78 (m), 1.19 (s, 3H), 0.69 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 142.7, 128.8, 77.3, 72.5, 56.9, 56.1, 50.2, 42.3, 39.7, 39.5,
36.9, 36.2, 36.0, 35.8, 32.1, 31.8, 28.2, 28.0, 25.4, 24.2, 23.8, 22.8, 22.5,
21.0, 20.5, 18.7, 11.8; IR (film, cm−1) 3406, 1455, 1366, 1072.
Supplemental data
This article contains supplemental data.
Acknowledgments
The authors thank all members of the Zoncu Lab for
helpful insights. The research reported in this publication
was supported in part by the National Institutes of Health
S10 program under award number 1S10RR026866-01.
Author contributions
O. M. and R. Z. conceived and designed the study; O. M.
performed all experiments except for the following; P. J. H.
Z. harvested and stained liver sections; C. B. extracted and
analyzed lipids for DNL measurements by mass spectrom-
etry; R. V. E. carried out the oxysterol screen; X. J. extracted,
analyzed, and quantified oxysterols in serum and liver; M. Q.
synthesized ent-4HC; O. M. and R. Z. wrote the article. D. S.
O., D. F. C., D. K. N., A. S., and E. J. W. helped with data




Funding and additional information
This work was supported by National Institutes of Health
R01GM127763 and R01GM130995 to R. Z., a National
Niemann-Pick foundation postdoctoral fellowship to O. M., a
National Institutes of Health R01 HL067773 to D. S. O. and D.
F. C. The Taylor Family Institute for Innovative Psychiatric
Research to D. F. C. The content is solely the responsibility of
the authors and does not necessarily represent the official
views of the National Institutes of Health. Primary mouse
hepatocytes were provided by core services of the UCSF
Liver Center (grant no. P30 DK026743).
Conflict of interest
R. Z. is cofounder, scientific advisor, and stockholder with
Frontier Medicines Corp. All other authors declare that they
have no conflicts of interest with the contents of this article.
Abbreviations
4β-HC, 4β-hydroxycholesterol; DNL, de novo lipogenesis;
DPBS, dulbecco’s phosphate buffered saline; ent-4HC,
enantiomer of 4β-HC; EtOAc, ethyl acetate; HC, hydrox-
ycholesterol; LD, lipid droplet; LDS, lipid-depleted serum;
mTOR, mechanistic Target of Rapamycin; NAFLD, nonal-
coholic fatty liver disease; PI3K, phosphatidylinositol 3-
kinase; THF, tetrahydrofuran.
Manuscript received October 7, 2020, and in revised from
January 6, 2021. Published, JLR Papers in Press, February 23,
2021, https://doi.org/10.1016/j.jlr.2021.100051
REFERENCES
1. Nohturfft, A., and Zhang, S. C. (2009) Coordination of lipid
metabolism in membrane biogenesis. Annu. Rev. Cell Dev. Biol. 25,
539–566
2. Thelen, A. M., and Zoncu, R. (2017) Emerging roles for the
lysosome in lipid metabolism. Trends Cell Biol. 27, 833–850
3. van Meer, G., Voelker, D. R., and Feigenson, G. W. (2008) Mem-
brane lipids: where they are and how they behave. Nat. Rev. Mol.
Cell Biol. 9, 112–124
4. Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R., and Man-
gelsdorf, D. J. (1996) An oxysterol signalling pathway mediated
by the nuclear receptor LXR alpha. Nature. 383, 728–731
5. Kalaany, N. Y., and Mangelsdorf, D. J. (2006) LXRS and FXR: the
yin and yang of cholesterol and fat metabolism. Annu. Rev.
Physiol. 68, 159–191
6. Repa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J. M.,
Shimomura, I., et al. (2000) Regulation of mouse sterol regula-
tory element-binding protein-1c gene (SREBP-1c) by oxysterol
receptors, LXRalpha and LXRbeta. Genes Dev. 14, 2819–2830
7. Yoshikawa, T., Shimano,H., Amemiya-Kudo,M., Yahagi, N., Hasty, A.
H.,Matsuzaka,T., et al. (2001) Identificationof liverXreceptor-retinoid
X receptor as an activator of the sterol regulatory element-binding
protein 1c gene promoter.Mol. Cell Biol. 21, 2991–3000
8. Costet, P., Luo, Y., Wang, N., and Tall, A. R. (2000)
Sterol-dependent transactivation of the ABC1 promoter by the
liver X receptor/retinoid X receptor. J. Biol. Chem. 275,
28240–28245
9. Peet, D. J., Turley, S. D., Ma, W., Janowski, B. A., Lobaccaro, J. M.,
Hammer, R. E., et al. (1998) Cholesterol and bile acid metabolism
are impaired in mice lacking the nuclear oxysterol receptor
LXR alpha. Cell. 93, 693–704
10. Svensson, S., Ostberg, T., Jacobsson, M., Norstrom, C., Stefansson,
K., Hallen, D., et al. (2003) Crystal structure of the heterodimeric
complex of LXRalpha and RXRbeta ligand-binding domains in
a fully agonistic conformation. EMBO J. 22, 4625–4633
11. Hong, C., Bradley, M. N., Rong, X., Wang, X., Wagner, A., Gri-
jalva, V., et al. (2012) LXRalpha is uniquely required for maximal
reverse cholesterol transport and atheroprotection in ApoE-
deficient mice. J. Lipid Res. 53, 1126–1133
12. Calkin, A. C., and Tontonoz, P. (2010) Liver x receptor signaling
pathways and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30,
1513–1518
13. Joseph, S. B., McKilligin, E., Pei, L., Watson, M. A., Collins, A. R.,
Laffitte, B. A., et al. (2002) Synthetic LXR ligand inhibits the
development of atherosclerosis in mice. Proc. Natl. Acad. Sci. U.S.A.
99, 7604–7609
14. Terasaka, N., Hiroshima, A., Koieyama, T., Ubukata, N., Mor-
ikawa, Y., Nakai, D., et al. (2003) T-0901317, a synthetic liver X
receptor ligand, inhibits development of atherosclerosis in LDL
receptor-deficient mice. FEBS Lett. 536, 6–11
15. Azzout-Marniche, D., Becard, D., Guichard, C., Foretz, M., Ferre,
P., and Foufelle, F. (2000) Insulin effects on sterol regulatory-
element-binding protein-1c (SREBP-1c) transcriptional activity
in rat hepatocytes. Biochem. J. 350 Pt 2, 389–393
16. Horton, J. D., Goldstein, J. L., and Brown, M. S. (2002) SREBPs:
activators of the complete program of cholesterol and fatty acid
synthesis in the liver. J. Clin. Invest. 109, 1125–1131
17. Ricoult, S. J., and Manning, B. D. (2013) The multifaceted role of
mTORC1 in the control of lipid metabolism. EMBO Rep. 14,
242–251
18. Grefhorst, A., Elzinga, B. M., Voshol, P. J., Plosch, T., Kok, T.,
Bloks, V. W., et al. (2002) Stimulation of lipogenesis by pharma-
cological activation of the liver X receptor leads to production
of large, triglyceride-rich very low density lipoprotein particles.
J. Biol. Chem. 277, 34182–34190
19. Schultz, J. R., Tu, H., Luk, A., Repa, J. J., Medina, J. C., Li, L., et al.
(2000) Role of LXRs in control of lipogenesis. Genes Dev. 14,
2831–2838
20. Cai, J., Zhang, X. J., and Li, H. (2018) Progress and challenges in
the prevention and control of nonalcoholic fatty liver disease.
Med. Res. Rev.
21. Mutemberezi, V., Guillemot-Legris, O., and Muccioli, G. G. (2016)
Oxysterols: From cholesterol metabolites to key mediators. Prog.
Lipid Res. 64, 152–169
14 J. Lipid Res. (2021) 62 100051
22. Guillemot-Legris, O., Mutemberezi, V., and Muccioli, G. G. (2016)
Oxysterols in metabolic syndrome: from bystander molecules to
bioactive lipids. Trends Mol. Med. 22, 594–614
23. Poli, G., Biasi, F., and Leonarduzzi, G. (2013) Oxysterols
in the pathogenesis of major chronic diseases. Redox Biol. 1,
125–130
24. Nury, T., Zarrouk, A., Vejux, A., Doria, M., Riedinger, J. M.,
Delage-Mourroux, R., et al. (2014) Induction of oxiapoptophagy,
a mixed mode of cell death associated with oxidative stress,
apoptosis and autophagy, on 7-ketocholesterol-treated 158N
murine oligodendrocytes: impairment by alpha-tocopherol.
Biochem. Biophys. Res. Commun. 446, 714–719
25. Janowski, B. A., Grogan, M. J., Jones, S. A., Wisely, G. B., Kliewer,
S. A., Corey, E. J., et al. (1999) Structural requirements of ligands
for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc.
Natl. Acad. Sci. U.S.A. 96, 266–271
26. Adams, C. M., Reitz, J., De Brabander, J. K., Feramisco, J. D., Li, L.,
Brown, M. S., et al. (2004) Cholesterol and 25-hydroxycholesterol
inhibit activation of SREBPs by different mechanisms, both
involving SCAP and Insigs. J. Biol. Chem. 279, 52772–52780
27. Radhakrishnan, A., Ikeda, Y., Kwon, H. J., Brown, M. S., and
Goldstein, J. L. (2007) Sterol-regulated transport of SREBPs from
endoplasmic reticulum to Golgi: oxysterols block transport by
binding to Insig. Proc. Natl. Acad. Sci. U.S.A. 104, 6511–6518
28. Nury, T., Samadi, M., Varin, A., Lopez, T., Zarrouk, A., Boumh-
ras, M., et al. (2013) Biological activities of the LXRalpha and beta
agonist, 4beta-hydroxycholesterol, and of its isomer, 4alpha-
hydroxycholesterol, on oligodendrocytes: effects on cell growth
and viability, oxidative and inflammatory status. Biochimie. 95,
518–530
29. Ignatova, I. D., Angdisen, J., Moran, E., and Schulman, I. G. (2013)
Differential regulation of gene expression by LXRs in response
to macrophage cholesterol loading. Mol. Endocrinol. 27, 1036–1047
30. Ishimoto, K., Nakamura, H., Tachibana, K., Yamasaki, D., Ota, A.,
Hirano, K., et al. (2009) Sterol-mediated regulation of human
lipin 1 gene expression in hepatoblastoma cells. J. Biol. Chem. 284,
22195–22205
31. Shimomura, I., Shimano, H., Korn, B. S., Bashmakov, Y., and
Horton, J. D. (1998) Nuclear sterol regulatory element-binding
proteins activate genes responsible for the entire program of
unsaturated fatty acid biosynthesis in transgenic mouse liver. J.
Biol. Chem. 273, 35299–35306
32. Peng, D., Hiipakka, R. A., Xie, J. T., Dai, Q., Kokontis, J. M.,
Reardon, C. A., et al. (2011) A novel potent synthetic steroidal liver
X receptor agonist lowers plasma cholesterol and triglycerides
and reduces atherosclerosis in LDLR(-/-) mice. Br. J. Pharmacol.
162, 1792–1804
33. Calvisi, D. F., Wang, C., Ho, C., Ladu, S., Lee, S. A., Mattu, S., et al.
(2011) Increased lipogenesis, induced by AKT-mTORC1-RPS6
signaling, promotes development of human hepatocellular
carcinoma. Gastroenterology. 140, 1071–1083
34. Li, L., Che, L., Tharp, K. M., Park, H. M., Pilo, M. G., Cao, D., et al.
(2016) Differential requirement for de novo lipogenesis in
cholangiocarcinoma and hepatocellular carcinoma of mice and
humans. Hepatology. 63, 1900–1913
35. Yabe, D., Komuro, R., Liang, G., Goldstein, J. L., and Brown, M. S.
(2003) Liver-specific mRNA for Insig-2 down-regulated by in-
sulin: implications for fatty acid synthesis. Proc. Natl. Acad. Sci. U.
S.A. 100, 3155–3160
36. Yecies, J. L., Zhang, H. H., Menon, S., Liu, S., Yecies, D., Lipovsky,
A. I., et al. (2011) Akt stimulates hepatic SREBP1c and lipogenesis
through parallel mTORC1-dependent and independent path-
ways. Cell Metab. 14, 21–32
37. Chen, G., Liang, G., Ou, J., Goldstein, J. L., and Brown, M. S. (2004)
Central role for liver X receptor in insulin-mediated activation
of Srebp-1c transcription and stimulation of fatty acid synthesis
in liver. Proc. Natl. Acad. Sci. U.S.A. 101, 11245–11250
38. Foretz, M., Pacot, C., Dugail, I., Lemarchand, P., Guichard, C., Le
Liepvre, X., et al. (1999) ADD1/SREBP-1c is required in the acti-
vation of hepatic lipogenic gene expression by glucose. Mol. Cell
Biol. 19, 3760–3768
39. Bodin, K., Andersson, U., Rystedt, E., Ellis, E., Norlin, M., Piku-
leva, I., et al. (2002) Metabolism of 4 beta -hydroxycholesterol in
humans. J. Biol. Chem. 277, 31534–31540
40. Kasichayanula, S., Boulton, D. W., Luo, W. L., Rodrigues, A. D.,
Yang, Z., Goodenough, A., et al. (2014) Validation of 4beta-
hydroxycholesterol and evaluation of other endogenous
biomarkers for the assessment of CYP3A activity in healthy
subjects. Br. J. Clin. Pharmacol. 78, 1122–1134
41. Herschlag, D., and Johnson, F. B. (1993) Synergism in transcrip-
tional activation: a kinetic view. Genes Dev. 7, 173–179
42. Salonurmi, T., Nabil, H., Ronkainen, J., Hyotylainen, T., Hauta-
jarvi, H., Savolainen, M. J., et al. (2020) 4beta-hydroxycholesterol
signals from the liver to regulate peripheral cholesterol trans-
porters. Front. Pharmacol. 11, 361
43. Kim, E. J., Kim, B. H., Seo, H. S., Lee, Y. J., Kim, H. H., Son, H. H.,
et al. (2014) Cholesterol-induced non-alcoholic fatty liver disease
and atherosclerosis aggravated by systemic inflammation. PLoS
One. 9, e97841
44. Serviddio, G., Bellanti, F., Villani, R., Tamborra, R., Zerbinati, C.,
Blonda, M., et al. (2016) Effects of dietary fatty acids and
cholesterol excess on liver injury: a lipidomic approach. Redox
Biol. 9, 296–305
45. Shimabukuro, M., Okawa, C., Yamada, H., Yanagi, S., Uematsu, E.,
Sugasawa, N., et al. (2016) The pathophysiological role of
oxidized cholesterols in epicardial fat accumulation and cardiac
dysfunction: a study in swine fed a high caloric diet with an
inhibitor of intestinal cholesterol absorption, ezetimibe. J. Nutr.
Biochem. 35, 66–73
46. Wooten, J. S., Wu, H., Raya, J., Perrard, X. D., Gaubatz, J., and
Hoogeveen, R. C. (2014) The influence of an obesogenic diet
on oxysterol metabolism in C57BL/6J mice. Cholesterol. 2014, 843468
47. Guillemot-Legris, O., Mutemberezi, V., Cani, P. D., and Muccioli,
G. G. (2016) Obesity is associated with changes in oxysterol
metabolism and levels in mice liver, hypothalamus, adipose tis-
sue and plasma. Sci. Rep. 6, 19694
48. Rong, S., Cortes, V. A., Rashid, S., Anderson, N. N., McDonald, J.
G., Liang, G., et al. (2017) Expression of SREBP-1c requires
SREBP-2-mediated generation of a sterol ligand for LXR in
livers of mice. Elife. 6
49. Hu, X., Li, S., Wu, J., Xia, C., and Lala, D. S. (2003) Liver X re-
ceptors interact with corepressors to regulate gene expression.
Mol. Endocrinol. 17, 1019–1026
50. Huuskonen, J., Fielding, P. E., and Fielding, C. J. (2004) Role of
p160 coactivator complex in the activation of liver X receptor.
Arterioscler. Thromb. Vasc. Biol. 24, 703–708
51. Oberkofler, H., Schraml, E., Krempler, F., and Patsch, W. (2003)
Potentiation of liver X receptor transcriptional activity by
peroxisome-proliferator-activated receptor gamma co-activator
1 alpha. Biochem. J. 371 (Pt 1), 89–96
52. Wagner, B. L., Valledor, A. F., Shao, G., Daige, C. L., Bischoff, E.
D., Petrowski, M., et al. (2003) Promoter-specific roles for liver X
receptor/corepressor complexes in the regulation of ABCA1
and SREBP1 gene expression. Mol. Cell Biol. 23, 5780–5789
53. Zhang, Y., Castellani, L. W., Sinal, C. J., Gonzalez, F. J., and
Edwards, P. A. (2004) Peroxisome proliferator-activated recep-
tor-gamma coactivator 1alpha (PGC-1alpha) regulates triglycer-
ide metabolism by activation of the nuclear receptor FXR. Genes
Dev. 18, 157–169
54. Bodin, K., Bretillon, L., Aden, Y., Bertilsson, L., Broome, U.,
Einarsson, C., et al. (2001) Antiepileptic drugs increase plasma
levels of 4beta-hydroxycholesterol in humans: evidence for
involvement of cytochrome p450 3A4. J. Biol. Chem. 276,
38685–38689
55. Huang, J. H., Zhang, C., Zhang, D. G., Li, L., Chen, X., and Xu, D.
X. (2016) Rifampicin-induced hepatic lipid accumulation: asso-
ciation with up-regulation of peroxisome proliferator-activated
receptor gamma in mouse liver. PLoS One. 11, e0165787
56. Zhou, J., Zhai, Y., Mu, Y., Gong, H., Uppal, H., Toma, D., et al.
(2006) A novel pregnane X receptor-mediated and sterol regu-
latory element-binding protein-independent lipogenic pathway.
J. Biol. Chem. 281, 15013–15020
57. He, J., Gao, J., Xu, M., Ren, S., Stefanovic-Racic, M., O'Doherty, R.
M., et al. (2013) PXR ablation alleviates diet-induced and genetic
obesity and insulin resistance in mice. Diabetes. 62, 1876–1887
58. Chudnovskiy, R., Thompson, A., Tharp, K., Hellerstein, M.,
Napoli, J. L., and Stahl, A. (2014) Consumption of clarified
grapefruit juice ameliorates high-fat diet induced insulin resis-
tance and weight gain in mice. PLoS One. 9, e108408
59. Neuschwander-Tetri, B. A., and Caldwell, S. H. (2003) Nonalco-
holic steatohepatitis: summary of an AASLD Single Topic
Conference. Hepatology. 37, 1202–1219
60. Higuchi, N., Kato, M., Shundo, Y., Tajiri, H., Tanaka, M., Yama-
shita, N., et al. (2008) Liver X receptor in cooperation with
4βHC coordinates cholesterol with fatty acid metabolism 15
SREBP-1c is a major lipid synthesis regulator in nonalcoholic
fatty liver disease. Hepatol. Res. 38, 1122–1129
61. Ikegami, T., Hyogo, H., Honda, A., Miyazaki, T., Tokushige, K.,
Hashimoto, E., et al. (2012) Increased serum liver X receptor
ligand oxysterols in patients with non-alcoholic fatty liver dis-
ease. J. Gastroenterol. 47, 1257–1266
62. Goldstein, J. L., Basu, S. K., and Brown, M. S. (1983) Receptor-
mediated endocytosis of low-density lipoprotein in cultured
cells. Methods Enzymol. 98, 241–260
63. Li, S., Brown, M. S., and Goldstein, J. L. (2010) Bifurcation of in-
sulin signaling pathway in rat liver: mTORC1 required for
stimulation of lipogenesis, but not inhibition of gluconeogen-
esis. Proc. Natl. Acad. Sci. U.S.A. 107, 3441–3446
64. Seglen, P. O. (1972) Preparation of rat liver cells. I. Effect of Ca 2
+ on enzymatic dispersion of isolated, perfused liver. Exp. Cell
Res. 74, 450–454
65. Benjamin, D. I., Li, D. S., Lowe, W., Heuer, T., Kemble, G., and
Nomura, D. K. (2015) Diacylglycerol metabolism and signaling is
a driving force underlying FASN inhibitor sensitivity in cancer
cells. ACS Chem. Biol. 10, 1616–1623
66. Covey, D. F. (2006) Ent-steroids chemistry and biology. Polish J.
Chem. 80, 511–522
67. Wicha, J., and Bal, K. (1978) Synthesis of 21-hydroxycholesterol
and 25-hydroxycholesterol from 3β-hydroxyandrost-5-en-17-
one. A method for the stereospecific construction of sterol
side-chains. J. C. S. Perkin I. 1282–1288
68. Nury, T., Samadi, M., Zarrouk, A., Riedinger, J. M., and Lizard, G.
(2013) Improved synthesis and in vitro evaluation of the
cytotoxic profile of oxysterols oxidized at C4 (4α- and
4β-hydroxycholesterol) and C7 (7-ketocholesterol, 7α- and 7β-
hydroxycholesterol) on cells of the central nervous system. Eur.
J. Med. Chem. 70, 558–567
16 J. Lipid Res. (2021) 62 100051
